Proposed Strategies for Designing and Analysing Sepsis Trials

  • Peter A. Lachenbruch
  • Jawahar Tiwari
Part of the Lecture Notes in Statistics book series (LNS, volume 123)


We discuss the design and analysis of trials of drugs and biologics designed to combat sepsis. We consider the variety of trials that have been conducted, and comment on the problems that have occurred in their conduct. These include variation in populations, therapies, controls, and endpoints. Optimistic estimates of effect sizes have led to studies which have been underpowered. Analyses using the proportional hazards model may be underpowered if the data do not satisfy the assumption of proportionality.


Septic Shock Risk Score Risk Index National Hospital Discharge Survey Sepsis Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bone, R. C., Balk, R. A., Cerra, F. C., et al. (1992). Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest, 101, 1656–1662.CrossRefGoogle Scholar
  2. FDA (1987). Guidelines for the Format and Content of the Clinical and Statistical Sections of New Drug Applications.Google Scholar
  3. Fleming, T. R. and Harrington, D. P. (1991). Counting Processes and Survival Analysis. New York: John Wiley and Sons.MATHGoogle Scholar
  4. Knaus, W. A., Harrell, F. E., Fisher, C. J., et al. (1993). The clinical evaluation of new drugs for sepsis: a prospective study design based on survival analysis. Journal of the American Medical Association., 270(10), 1233–1241.CrossRefGoogle Scholar
  5. Knaus, W. A., Harrell, F. E., LaBreque, J. F., et al. (1996). Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. Critical Care Medicine, 24, 46–56.CrossRefGoogle Scholar
  6. Lemeshow, S., Teres, D., Klar, J., et al. (1993). Mortality Probability Models (MPM II) based on an international cohort of intensive care unit patients. Journal of the American Medical Association. 270(20), 2478–2486.CrossRefGoogle Scholar
  7. MMWR (1990). Increase in National Hospital Discharge Survey Rates for Septicemia — United States, 1979–1987. 39, 31–34.Google Scholar
  8. Siegel, J. P. (1994). Letter to Brussels Roundtable Consensus Conference. Personal communication.Google Scholar
  9. Ziegler, E. J., Fisher, C. J., Sprung, C. L., et al. (1991). Treatment of gram-Negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. New England Journal of Medicine, 324, 429–436.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1997

Authors and Affiliations

  • Peter A. Lachenbruch
  • Jawahar Tiwari

There are no affiliations available

Personalised recommendations